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Abstract The aim of this study is to evaluate a new tumour
marker, HE4, in comparison with CA 125 and the Risk of
Ovarian Malignancy Algorithm (ROMA) in healthy women
and in patients with benign and malignant gynaecological
diseases. CA 125 and HE4 serum levels were determined in
66 healthy women, 285 patients with benign gynaecological
diseases (68 endometriosis, 56 myomas, 137 ovarian cysts
and 24 with other diseases), 33 patients with non-active
gynaecological cancer and 143 with active gynaecological
cancer (111 ovarian cancers). CA 125 and HE4 cut-offs were
35U/mLand150pmol/L,respectively.ROMAalgorithmcut-
off was 13.1 and 27.7 for premenopausal or postmenopausal
women, respectively. HE4, CA 125 and ROMA results were
abnormalin1.5%,13.6%and25.8%ofhealthywomenandin
1.1%, 30.2% and 12.3% of patients with benign diseases,
respectively. Among patients with cancer, HE4 (in contrast to
CA 125) had significantly higher concentrations in ovarian
cancer than in other malignancies (p<0.001). Tumour marker
sensitivity in ovarian cancer was 79.3% for HE4, 82.9% for
CA 125 and 90.1% for ROMA. Both tumour markers, HE4
and CA 125 were related to tumour stage and histological
type, with the lowest concentrations in mucinous tumours. A
significantly higher area under the ROC curve was
obtained with ROMA and HE4 than with CA 125 in
the differential diagnosis of benign gynaecological
diseases versus malignant ovarian cancer (0.952, 0.936
and 0.853, respectively). Data from our population
indicate that ROMA algorithm might be further improved if
it is used only in patients with normal HE4 and abnormal CA
125 serum levels (cancer risk for this profile is 44.4%).
ROMA algorithm in HE4 positive had a similar sensi-
tivity and only increases the specificity by 3.2%
compared to HE4 alone.
Keywords HE4.CA-125.ROMA.Tumour markers.
Ovarian cancer.Abdominal masses.Risk of malignancy
Introduction
The common symptoms of ovarian cancer are vague and
similar to those observed in other benign conditions [1–3]
so that most patients are diagnosed at advanced stages. This
explains that ovarian cancer is the fifth most common cause
of cancer death in women [1–4]. Despite advances in
treatment, there has been little change in the mortality rate
of ovarian cancer [1–3]. A diagnostic approach based on the
use of CA 125 in association with ultrasonography has been
suggested for the early diagnosis of ovarian cancer [2, 4–14].
However, this approach has several drawbacks including low
sensitivity and specificity [4–16]. Abnormal CA 125 serum
levels can be found in malignancies of different origin
including epithelial (endometrial, endocervix and lung
cancer) and non-epithelial malignancies (lymphomas) [4–6,
13–21]. Abnormal CA 125 serum levels may be also found
in several benign diseases, mainly those with effusions, liver
or renal failure and benign gynaecological conditions
(ovarian cysts, myomas and endometriosis) [4, 6, 13–22].
Sensitivity of CA 125 in ovarian cancer is related to tumour
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mately 50% of stage I patients and 80–90% in patients of
stages III–IV [2, 4–6, 11–16].
Recently, another tumour marker for ovarian cancer has
been proposed, the HE4 protein, frequently overexpressed
in ovarian cancers, especially in serous and endometrioid
histology [23–29]. However, HE4 is not specific of ovarian
cancer and some expression has also been found in other
malignancies mainly pulmonary and endometrial adenocar-
cinomas [30, 31]. Recently, our group reported that HE4
was more specific than CA 125 in benign and malignant
conditions [31]. HE4 serum levels may be abnormal mainly
in patients with renal failure or effusions and in patients
with lung carcinomas. Studies suggest that HE4 has a
similar sensitivity to CA 125, but an increased specificity
in patients with gynaecological malignancies as com-
pared with those with benign gynaecological disease
[31–37]. Likewise, different studies propose the use of a
Risk of Ovarian Malignancy Algorithm (ROMA) to
improve the sensitivity and specificity of the combined
use of both tumour markers in patients with abdominal
masses [9, 28, 32–36].
The aims of this study were:
1. To evaluate the HE4 and CA 125 serum levels in
healthy subjects and in patients with benign and
malignant gynaecological diseases
2. To compare the utility of the three parameters, HE4, CA
125 and ROMA, for risk stratification and diagnostic
purpose in patients with gynaecological diseases.
Material and methods
Patient population
We have determined HE4 serum levels in 66 healthy
women (20–91 years, median 49±SE 2.2 years) (34
premenopausal, 32 postmenopausal), 285 patients with
benign gynaecological diseases (17–90 years, median 40±
SE 0.8 years), 143 patients with active gynaecological
cancer (23–87 years, median 61±SE 1.2 years) and 33
patients without active disease (NED) after radical treat-
ment (23 adenocarcinomas of endometrium or endocervix,
six squamous cervical cancer and four with ovarian cancer).
The group with benign diseases included 137 patients with
ovarian cysts, 56 patients with myomas, 68 patients with
endometriosis, 14 patients with endometrial polyps and ten
patients with other diseases). Fifty-nine of these patients
were postmenopausal (median 61, range from 48 to 90 years
old), and the remaining 226 patients were premenopausal
(median 37.5, range 17–51 years old).
The group with malignant diseases, classified according
to the International Federation of Gynaecology and Obstet-
rics [38], included 143 patients with active cancer and
without renal failure or creatinine serum levels >1.5 mg/dl,
including 111 ovarian cancers (19 in stages I–II, 48 in stage
III and 44 in stage IV), 17 endometrial cancers (4 in stages
I–II, 13 in stages III–IV), 7 endocervical cancers (one in
stages I–II, six in stages III–IV) and 8 squamous cell
carcinomas of the cervix (one in stages I–II, seven in stages
III–IV).
Laboratory methods
The serum levels of CA 125 and HE4 were determined
using a chemiluminescent enzyme immunoassay on the
Architect® Analyzer (Abbott Laboratories, Chicago, IL)
with an inter-assay precision of CA 125 was 2.85%
(35.6 mU/mL), 2.5% (268.3 mU/mL) and 1.96%
(623 mU/mL). The inter-assay precision of HE4 was
3.5% (49.7 pmol/L), 3.6% (168.1 pmol/L) and 3.8%
(648.2 pmol/L). We have considered 35 U/mL and
150 pmol/L as the upper limits of normality for CA 125
and HE4, respectively. ROMA algorithm was calculated
according to the formulae described previously [9, 33]
using logistic regression analysis for premenopausal
(predictive index:  12 þ 2:38   LN HE4 ðÞ þ 0:0626  
LN CA125 ðÞ ) and postmenopausal women (predictive
index:  8:09 þ 1:04   LN HE4 ðÞ þ 0:732   LN CA125 ðÞ ).
We have considered positive (risk) PI results ≥13.1 and
27.7 for premenopausal and postmenopausal women,
respectively [9, 33]. This protocol was approved by the
ethical committee of Hospital Clinic.
Statistical analysis
Values were finally reported as median (range). All the data
were analysed with SPSS statistical software (version 14.0;
SPSS Inc. Chicago, IL). Tumour marker levels between
groups were compared using the Kruskall–Wallis and
Mann–Whitney test. The level of statistical significance
was set at p<0.05. Sensitivity was considered as the ratio
between the numbers of patients with malignancy whose
marker levels were elevated over the total number of
patients with malignancy. Specificity was calculated as the
ratio between the number of patients without malignancy
and normal tumour marker values by the total number of
patients without malignancy. Positive predictive values
were calculated as the ratio among the cases with elevated
tumour markers and malignancy and the sum of all the
cases with elevated tumour markers. The negative predic-
tive value was calculated by the ratio among the patients
with negative results and without malignancy and the total
number of patients with negative results. Efficacy value was
1088 Tumor Biol. (2011) 32:1087–1095calculated by the ratio among patients with cancer and
positive results plus patients without cancer and negative
results and the total number of patients studied. Youden
indices (J) were calculated according to the equation
J ¼ sensitivity þ specificity   1 ðÞ . Receiver operator char-
acteristic (ROC) curves were assessed for HE4 and CA 125
(cut-off: 150 pmol/L, 35 U/mL) and compared using the
DeLong mathematical model [39].
Results
The results of CA 125 and HE4 measurements in the different
populationsstudiedareshowninTable1. Significantly higher
CA 125 serum levels were found in premenopausal women
than in postmenopausal women (p=0.001). For HE4, higher
concentrations in postmenopausal women were found but the
data were not statistically significant.
In patients with benign diseases, abnormal serum levels
of HE4 and CA 125 were found in 1.1% (3 of 285) and
30.2% (86 of 285) of patients, respectively. CA 125 false
positive results were mainly found in premenopausal
women with abnormal serum levels in 32.3% of the
patients with gynaecological benign diseases in contrast to
22% of them found in postmenopausal women. The use of
ROMA algorithm reduces the proportion of CA 125 false
positive results in the total group as well as in pre- or
postmenopausal women (Table 1).
For CA 125, the most common cause of elevated
results was endometriosis with abnormal values in 30 of
68 studied patients (44.1%). However, only 10.3% of
these patients with endometriosis had risk by the
ROMA algorithm.
Significantly higher serum concentrations of CA 125 and
HE4 (p=0.005) were found in patients with cancer than in
those with benign diseases (Table 1). Both tumour markers
showed a similar sensitivity in ovarian cancer, slightly
higher with CA 125 (82.9%) than with HE4 (79.3%).
Likewise, significantly higher concentrations of HE4 were
found in patients with ovarian cancer than in other
gynaecological malignancies. CA 125 is frequently abnor-
mal in gynaecological adenocarcinomas and in 25% of
squamous cell tumours, and a trend towards higher
concentrations in ovarian carcinoma was found, but differ-
ences were not statistically significant. ROMA algorithm is
not related to the tumour origin and results above the cut-
off suggest high risk in the majority of ovarian cancer and
adenocarcinomas as well as in a high proportion of patients
with squamous tumours.
Table 2 shows the CA 125 and HE4 serum levels in
patients with ovarian cancer, subdivided according to
tumour stage and histological type. Both tumour markers
were clearly related to stage with significantly higher
concentrations in advanced stages III–IV than in stages
I–II (p=0.001). However, no differences were found
between stages III and IV with either tumour marker.
Likewise, the use of both tumour markers together
improved the sensitivity obtained with only one tumour
marker in all the stages (Table 2). Risk established by the
ROMA algorithm showed a higher sensitivity than either
tumour marker individually and slightly lower than the
sensitivity obtained with the combined use of both tumour
markers (either positive) in all stages (Table 2).
HE4 and CA 125 were related to the histological type
with significantly higher serum concentrations of CA 125
(p=0.024) and HE4 (p=0.001) in serous papillary ovarian
cancer. No differences between mucinous tumours and
other histologies (no serous papillary) were found in
relation to the serum levels of these tumour markers. CA
125 had a higher sensitivity than HE4 in non-serous
histologies, mainly in mucinous tumours (Table 2).
Figure 1 shows the ROC curve evaluating the utility of
HE4, CA 125 serum levels and ROMA algorithm in the
diagnosis of ovarian malignancy comparing patients with
ovarian cancer and those with benign gynaecological
diseases. ROMA algorithm showed a slightly high area
under the curve than HE4 and both are significantly higher
than CA 125.
Table 3 shows the HE4, CA 125 and ROMA efficacy in
the differential diagnosis of ovarian cancer and patients
with benign gynaecological conditions. HE4 showed the
higher specificity and positive predictive value (PPV) in
the total group as well as in premenopausal and postmen-
opausal women. By contrast, ROMA showed the highest
sensitivity and negative predictive value (NPV) (mainly in
postmenopausal women) in all groups. HE4 had the
highest efficacy in the total group as well as in
premenopausal women and ROMA in postmenopausal
women.
The PPV was 96.7% (88/91) in patients with
abnormal HE4 and 97.8% (88/90) using the ROMA
algorithm in this subgroup of patients. Sensitivity was
similar (79.3%) and only one patient (1.1%) with
abnormal HE4 and no risk with the ROMA algorithm
were found and with the diagnosis of ovarian cyst.
Table 4 shows the accuracy of the risk of ovarian cancer
according to CA 125 serum levels and ROMA, subdivid-
ing the patients according to HE4 serum levels. It is
interesting to point out that in patients with HE4 in the
normal range, only in those patients with abnormal CA
125 and risk with the ROMA algorithm a significant
number of correctly detected cancer was found: 54.5% in
the total group, 37.5% in premenopausal women and
64.3% in postmenopausal women. Likewise, there is a
group of 23 patients (8% of the benign studied population)
with risk according the ROMA algorithm and with normal
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1090 Tumor Biol. (2011) 32:1087–1095values of both tumour markers (Table 4). None of these
patients had ovarian cancer.
Discussion
Different authors have suggested the use of serial CA 125
in combination with ultrasonography in postmenopausal
asymptomatic women as an aid in the early diagnosis of
ovarian cancer [2, 4–14]. These studies are mainly
performed in postmenopausal women due to the lack of
specificity in premenopausal women with abnormal levels
in different benign diseases, mainly related to endometri-
osis. Different studies reported a positive predictive value in
the diagnosis of ovarian cancer in asymptomatic women
ranging from 10% to 21% [2, 4–8, 12–16]. The major
drawback of using CA 125 as an initial step in such a
screening strategy is that up to 20% of ovarian cancers lack
expression of the antigen [2, 4–8, 12–16]. It is therefore
necessary to combine CA 125 with new tumour markers
that provide a better diagnostic efficiency [4, 6, 8, 13, 15,
16, 28, 33–36].
Specificity is a significant issue for CA 125. Abnormal
serum levels of CA 125 may be found in several benign and
malignant diseases other than ovarian cancer [2, 4–6, 13–22].
Despite these issues, CA 125 is used to differentiate benign
from malignant pelvic masses and is used as a prognostic
factor in the early diagnosis of recurrence or to assess
response to treatment [11–13, 15, 16, 32].
HE4 is part of a family of protease inhibitors that
functions in protective immunity which is overexpressed
in ovarian cancers, especially in serous and endome-
trioid histotype [26–28, 31, 40, 41]. It is secreted by the
cell and then detectable in the bloodstream of patients with
ovarian carcinoma via an enzyme immunoassay. Prelimi-
nary studies of HE4 reported a higher specificity than CA
125 in different benign and malignant conditions, exclud-
ing renal failure [31]. Patients with renal failure had very
high HE4 serum levels, undistinguishable from ovarian
cancer. For this reason, patients with this pathology were
excluded in our study. Excluding this disease, slightly
elevated HE4 serum levels were found in only one third of
patients with effusions or in 5% of patients with chronic
liver diseases [31].
The majority of HE4 studies in serum has been
published indicating that HE4 sensitivity and specificity in
gynaecological diseases are better than CA 125 and that
both tumour markers are complementary [9, 10, 32–36, 40,
41]. Our results confirm these previous studies and clearly
show that the use of HE4 may be important in the
differential diagnosis of ovarian cancer with other gynaeco-
logical conditions including premenopausal women [9, 10,
32–36, 40, 41]. However, HE4 as well as CA 125 are not
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Tumor Biol. (2011) 32:1087–1095 1091only found in ovarian carcinoma; abnormal levels may be
also found in gynaecological adenocarcinomas or in lung
cancer as was previously reported. Moore et al. [28, 33]
have previously indicated the HE4 expression in patients
with endometrial cancer had a clear relationship to tumour
stage. In our experience, HE4 has a better utility in the
differential diagnosis of ovarian cancer, and abnormal levels
were found in only one third of the patients with
endometrial or endocervical cancer and none with squa-
mous cervical cancer. By contrast, CA 125 is frequently
abnormal in all these malignancies.
To improve sensitivity and specificity, an algorithm,
ROMA, using both tumour markers, has been suggested
that indicates the ovarian cancer risk in patients with
111
285
Group
Ovarian cancer
Benign
gynaecological
no patients
,936
,853
,952
HE4
CA125
ROMA
Area
Fig. 1 HE4, CA 125 and
ROMA in the differential
diagnosis of ovarian cancer
and benign gynaecological
diseases
Table 3 Evaluation of HE4, CA 125 and ROMA efficacy in the determination of the risk of ovarian cancer (including only patients with benign
gynaecological diseases and ovarian cancer)
Sensitivity Specificity PPV NPV Efficacy Youden indices
HE4 88/111 (79.3%) 282/285 (98.9%) 88/91 (96.7%) 282/305 (92.5%) 370/396 (93.4%) 0.782
CA 125 92/111 (82.9%) 202/285 (70.9%) 92/175 (52.6%) 202/221 (91.4%) 294/396 (74.2%) 0.538
ROMA 100/111 (90.1%) 250/285 (87.7%) 100/135 (74%) 250/261 (95.8%) 350/396 (88.4%) 0.778
Premenopausal HE4 17/27 (63%) 226/226 (100%) 17/17 (100%) 226/236 (95.8%) 243/253 (90.9%) 0.63
CA 125 20/27 (74.1%) 156/226 (69%) 20/90 (22.2%) 156/163 (95.7%) 176/253 (69.6%) 0.431
ROMA 20/27 (74.1%) 201/226 (88.9%) 20/45 (44.4%) 201/208 (96.6%) 221/253 (87.4%) 0.630
Postmenopausal HE4 71/84 (84.5%) 56/59 (94.9%) 71/74 (96%) 56/69 (81.2%) 127/143 (88.8%) 0.794
CA 125 72/84 (85.7%) 46/59 (78.0%) 72/85 (84.7%) 46/58 (79.3%) 118/143 (82.5%) 0.637
ROMA 80/84 (95.2%) 49/59 (83.1%) 80/90 (88.9%) 49/53 (92.5%) 129/143 (90.2%) 0.841
PPV positive predictive value; NPV negative predictive value
1092 Tumor Biol. (2011) 32:1087–1095abdominal masses. ROC curve shows that ROMA algo-
rithm is the parameter with the highest discrimination
between ovarian cancer and gynaecological diseases. The
lower difference for the area under the ROC curve between
HE4 and ROMA compared to other studies might be
explained by the fact that in our population, the group of
premenopausal women was much larger than the group of
postmenopausal women. Due to the lower specificity of CA
125 in this group of patients, the superiority of ROMA is
diminished. A further optimization of the ROMA cut-offs
might need further investigation in a multicentric setup
assessing different populations. Also, our results clearly
show that the ROMA algorithm improves the specificity
found with CA 125, but decreases it in relation to HE4.
Twelve percent of patients without malignancy were
classified as risk by ROMA in contrast to the low
proportion of false positive results found with HE4
(1.1%). Likewise, ROMA algorithm is not useful to
establish the tumour origin, as it has a high sensitivity of
90.1% for ovarian cancer but also of 94.1% for endometrial
cancer or higher than 60% for cervical cancer.
HE4 is a tumour marker with higher efficacy than CA
125. HE4 positive predictive value is 96.7% (high) in the
total group, 100% in premenopausal women and 96% in
postmenopausal women. However, the main problem to use
HE4 alone as a help in the diagnosis of pelvic mass is that
sensitivity in ovarian cancer is not enough with 20.7% of
false negative results [4, 14, 15, 33–36]. It is of note that
HE4 showed a higher sensitivity than CA 125 in early
stages and by contrast CA 125 was the most sensitive
tumour marker in an advance stage. CA 125 can be used
together with HE4 but the problem is the high proportion of
false positive results (PPV+ 52.6%), mainly in premeno-
pausal women (PPV+ 22.2%). The main advantage of the
ROMA algorithm is the sensitivity, classifying 90.1% of
patients with ovarian cancer as risk group, 7.2% more
compared to CA 125 and 10.8% more than for HE4. An
increase in the sensitivity is independent of menopausal
status (Table 3). However, the false positive results
associated to CA 125 decrease the ROMA PPV, mainly in
premenopausal women. These data explain why ROMA is
mainly useful (higher efficacy and Youden indices) in
postmenopausal women. However, it is interesting to notice
that ROMA had a low PPV in premenopausal women but
its NPV is high, indicating that is very unusual to find
ovarian cancer with ROMA or HE4 negative. These data
are interesting if we consider that the ovarian cancer
prevalence in our study was 10.7% (27/253 patients) in
the premenopausal group and 58.7% (84/143 patients) in
the postmenopausal group (Table 3). These results are in
concordance with the last publication of Montagnana et al.
[41] that reported that ROMA is mainly useful in
postmenopausal women. Likewise, Montagnana et al. [41]
reported that HE4 is the most efficient tumour marker, with
no clear advantages including CA 125, as we found in our
study. More studies are necessary to clarify the HE4 cut-
point as well as the best cut-offs for ROMA.
Results obtained in our study can be summarised by the
fact that HE4 alone is useful in supporting the diagnosis of
ovarianmasses.Inour population,the additionofCA 125and
ROMA trying to increase sensitivity is not optimal in those
patients with abnormal HE4 because the high specificity of
HE4 already indicates a high risk for ovarian cancer. The PPV
of HE4 is 96.7% and increases until 97.8% when ROMA is
also abnormal. In summary, the use of ROMA algorithm in
HE4+ patients does not increase sensitivity but only increases
the PPV by 3.2% (three patients). These results are in
discordance with those published by van Gorp et al. [40]
suggesting that ROMA and HE4 did not increase the
detection rate of malignant diseases compared to CA 125.
These results are surprising in relation to our data or other
publications because there is an agreement in the fact that
HE4 is more specific than CA 125 and that the sensitivity is
at least similar, and that CA 125 false positive results in
patients with gynaecological diseases is high, mainly in
premenopausal women [9, 31–35, 41].
Table 4 Evaluation of CA 125 and ROMA efficiency in the diagnosis of ovarian cancer (excluding other gynaecological malignancies) according
to HE4 results (> or <150 pmol/L)
PPV PPV in premenopausal women PPV in postmenopausal women
HE4 >150 pmol/L CA 125+ ROMA+ 75/77 (97.4%) 13/13 (100%) 62/64 (96.9%)
CA 125− ROMA+ 13/13 (100%) 4/4 (100%) 9/9 (100%)
CA 125+ ROMA− –– –
CA 125− ROMA− 0/1 (0%) – 0/1 (0%)
HE4 <150 pmol/L CA 125+ ROMA+ 12/22 (54.5%) 3/8 (37.5%) 9/14 (64.3%)
CA 125− ROMA + 0/23 (0%) 0/20 (0%) 0/3 (0%)
CA 125+ ROMA− 5/76 (6.6%) 4/69 (5.8%) 1/7 (14.3%)
CA 125− ROMA− 6/184 (3.3%) 3/139 (2.2%) 3/45 (6.7%)
PPV positive predictive value
Tumor Biol. (2011) 32:1087–1095 1093An optimised application of the ROMA algorithm may
result in an improved CA 125 specificity in those patients
with HE4 negative results. Patients with abnormal CA 125
had a risk by the ROMA algorithm of 44.4%, increasing the
HE4 sensitivity in 12 (10.8%) patients with ovarian cancer.
By contrast, it is possible to find that 23 patients (8% of the
benign studied population) had risk by the ROMA
algorithm with negativity of both markers that are used in
this calculation. None of these patients had ovarian cancer.
ROMA algorithm was calculated for optimising surgical
referral of patients with abdominal masses to either
oncologists or non-oncologists. Twenty-three of our patients
with risk by ROMA and with negativity of both tumour
markers had benign gynaecological diseases, the majority
of them with abdominal masses or endometriosis. However,
the risk to miss early stage of cancers in this group needs to
be determined by larger populations.
Our results indicate that the best algorithm to suggest
ovarian cancer risk may be is to classify those patients with
HE4 positive results as high risk and to determine the risk
by the ROMA algorithm for patients with normal HE4 but
abnormal CA 125 values. These criteria allow us to obtain a
high sensitivity (90.1% 100/111 ovarian cancer) and
increase the specificity with a lower proportion of false
positive results (PPV+ 82.6%, 100/121 patients). Only 11
patients with ovarian cancer were missed using these
criteria and six of them had mucinous tumours. In the
assessment of histological types HE4 and CA, 125 are
related to mucinous tumours with the lowest sensitivity and
median concentrations [26, 28, 31, 40, 41]. Using this
approach, we were able to suggest the diagnosis in 94.9%
(93/98) of patients with non-mucinous ovarian cancer.
Other markers or approaches may be used when we suspect
mucinous tumours as for example CA 19.9 [11, 16].
In conclusion, HE4 is the tumour marker of choice in
ovarian cancer, with a higher sensitivity in early stages,
specificity and efficiency than CA 125 and ROMA
algorithm. Our data indicate a potential to improve this
algorithm mainly by using it in those patients with HE4-
negative and with CA 125-positive results. The use of this
combination allows to increase the tumour marker utility in
the diagnosis of pelvic masses with a sensitivity of 90.1%
(95% in non-mucinous tumours) and a specificity of 82.1%.
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